Differentiated HIV services for transgender people in four South African districts: population characteristics and HIV care cascade.

HIV services South Africa differentiated service delivery models gender-affirming hormone therapy transgender

Journal

Journal of the International AIDS Society
ISSN: 1758-2652
Titre abrégé: J Int AIDS Soc
Pays: Switzerland
ID NLM: 101478566

Informations de publication

Date de publication:
10 2022
Historique:
received: 11 01 2022
accepted: 30 07 2022
entrez: 13 10 2022
pubmed: 14 10 2022
medline: 15 10 2022
Statut: ppublish

Résumé

Transgender people in South Africa are disproportionately affected by HIV, discrimination and stigma. Access to healthcare and health outcomes are poor. Although integrating gender-affirming healthcare with differentiated HIV prevention, care and treatment services has shown improvement in HIV service uptake and health outcomes among transgender people, evidence is lacking on the implementation of differentiated service delivery models in southern Africa. This article describes a differentiated service delivery model across four South African sites and transgender individuals who access these services. We assess whether hormone therapy (HT) is associated with continued use of pre-exposure prophylaxis (PrEP) and viral load suppression. In 2019, differentiated healthcare centres for transgender individuals opened in four South African districts, providing gender-affirming healthcare and HIV services at a primary healthcare level. Routine programme data were collected between October 2019 and June 2021. Descriptive statistics summarized patient characteristics and engagement with HIV prevention and treatment services. We conducted a multivariate logistic regression analysis to determine whether HT was associated with viral load suppression and PrEP continued use. In the review period, we reached 5636 transgender individuals through peer outreach services; 86% (4829/5636) of them accepted an HIV test and 62% (3535/5636) were linked to clinical services. Among these, 89% (3130/3535) were transgender women, 5% (192/3535) were transgender men and 6% (213/3535) were gender non-conforming individuals. Of those who received an HIV test, 14% (687/4829) tested positive and 91% of those initiated antiretroviral treatment. Viral load suppression was 75% in this cohort. PrEP was accepted by 28% (1165/4142) of those who tested negative. Five percent (161/3535) reported ever receiving HT through the public healthcare system. Service users who received HT were three-fold more likely to achieve viral load suppression. We did not find any association between HT and continued use of PrEP. A differentiated HIV and gender-affirming service delivery model at a primary healthcare level is feasible and can enhance service access in South Africa. HT can improve HIV clinical outcomes for transgender people. As trust is established between the providers and population, uptake of HIV testing and related services may increase further.

Identifiants

pubmed: 36225147
doi: 10.1002/jia2.25987
pmc: PMC9557019
doi:

Substances chimiques

Hormones 0

Types de publication

Journal Article Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

e25987

Subventions

Organisme : PEPFAR
ID : 72067418CA00027
Pays : United States

Informations de copyright

© 2022 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.

Références

J Acquir Immune Defic Syndr. 2016 Aug 15;72 Suppl 3:S235-42
pubmed: 27429189
AIDS Behav. 2019 Sep;23(9):2588-2599
pubmed: 31263998
J Sex Med. 2012 Feb;9(2):531-41
pubmed: 22145968
J Acquir Immune Defic Syndr. 2021 May 1;87(1):e150-e158
pubmed: 33492024
Bull World Health Organ. 2017 Feb 1;95(2):154-156
pubmed: 28250518
J Int AIDS Soc. 2016 Jul 17;19(3 Suppl 2):20779
pubmed: 27431466
Afr J Prim Health Care Fam Med. 2019 Jul 10;11(1):e1-e9
pubmed: 31296016
AIDS. 2014 Jun 19;28(10):1509-19
pubmed: 24809629
PLoS One. 2020 Apr 30;15(4):e0228620
pubmed: 32352969
Psychoneuroendocrinology. 2012 May;37(5):662-70
pubmed: 21937168
Lancet Infect Dis. 2013 Mar;13(3):214-22
pubmed: 23260128
Int J Equity Health. 2016 Jan 22;15:16
pubmed: 26800682
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Front Public Health. 2022 Jun 17;10:691729
pubmed: 35784260
Glob Public Health. 2016 Aug-Sep;11(7-8):1060-75
pubmed: 26963756
J Int AIDS Soc. 2016 Oct 18;19(7(Suppl 6)):21105
pubmed: 27760683
PLoS Med. 2017 Nov 7;14(11):e1002422
pubmed: 29112689
Lancet. 2016 Jul 23;388(10042):412-436
pubmed: 27323919
Am J Public Health. 2013 Oct;103(10):1830-6
pubmed: 23948009
Am J Public Health. 2009 Apr;99(4):713-9
pubmed: 19150911
Open Forum Infect Dis. 2021 Jul 30;8(9):ofab404
pubmed: 34514019
J Int AIDS Soc. 2019 Apr;22(4):e25270
pubmed: 31037858
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
J Acquir Immune Defic Syndr. 2016 Aug 15;72 Suppl 3:S226-9
pubmed: 27429187
J Int AIDS Soc. 2014 Jul 18;17:19320
pubmed: 25043380
BMJ Glob Health. 2020 Nov;5(11):
pubmed: 33239337

Auteurs

Rutendo Bothma (R)

Wits Reproductive Health and HIV Institute (Wits RHI), University of the Witwatersrand, Johannesburg, South Africa.

Cara O'Connor (C)

Wits Reproductive Health and HIV Institute (Wits RHI), University of the Witwatersrand, Johannesburg, South Africa.

Jolie Nkusi (J)

Wits Reproductive Health and HIV Institute (Wits RHI), University of the Witwatersrand, Johannesburg, South Africa.

Vusi Shiba (V)

Wits Reproductive Health and HIV Institute (Wits RHI), University of the Witwatersrand, Johannesburg, South Africa.

Jacob Segale (J)

Wits Reproductive Health and HIV Institute (Wits RHI), University of the Witwatersrand, Johannesburg, South Africa.

Luyanda Matsebula (L)

Wits Reproductive Health and HIV Institute (Wits RHI), University of the Witwatersrand, Johannesburg, South Africa.

J Joseph Lawrence (JJ)

United States Agency for International Development/Southern Africa, City of Tshwane, South Africa.

L Leigh-Ann van der Merwe (LL)

Social, Health & Empowerment Feminist Collective of Transgender Women of Africa, East London, South Africa.

Matthew Chersich (M)

Wits Reproductive Health and HIV Institute (Wits RHI), University of the Witwatersrand, Johannesburg, South Africa.

Naomi Hill (N)

Wits Reproductive Health and HIV Institute (Wits RHI), University of the Witwatersrand, Johannesburg, South Africa.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH